The prevalence of psychotic disorders is of 0.85% in the world population. Among these disorders, the most important are: schizophrenia, bipolar psychosis and organic psychoses. Treatment depends on the origin of the psychotic disorder, since antipsychotic medications, psychological therapy and various psychosocial supports are used. The lack of effect of pharmacological treatment of psychotic disorders may be in large part due to genetic causes, as the variation in the human genome is one of the most important factors responsible for modulating the individual response to drugs.
The genetic profile FG – Neuro-Psychosis studies the main metabolizing enzymes involved in the metabolism of the antipsychotics drugs as well as carrier proteins and therapeutic targets. The analysis provides relevant information about the 14 drugs most commonly used in medicine, based on the study of 17 genetic polymorphisms described in the scientific literature, present in the enzymes of the cytochrome P450 system (CYP2D6, CYP3A4, CYP1A2) and in the gene CACNG2.
• Patients on pharmacological treatment who wish to customize medication based on their genetic profile
• Patients with drug side effects
• Patients in whom pharmacological treatments do not show the expected results.
Next Generation Sequencing (NGS)
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Detailed report including, in addition to the type of metabolism of each enzyme, which drugs can generate toxic effects and adverse reactions, as well as dose recommendations.
• Information provided by the analysis allows the selection of the most appropriate drug, and determines the most appropriate dose for each patient.
• Genetic counseling available at no additional cost, according to the needs of each client.
DOCUMENTATION – Available on Extranet for clients:
• Informed Consent
• Clinical Questionnaire
• Fasting is not necessary for the test.